Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | REPL |
---|---|---|
09:32 ET | 20579 | 9.08 |
09:34 ET | 1044 | 9.2355 |
09:36 ET | 500 | 9.185 |
09:38 ET | 1003 | 9.1027 |
09:39 ET | 6440 | 9.01 |
09:41 ET | 500 | 8.97 |
09:43 ET | 200 | 8.99 |
09:45 ET | 5858 | 9.11 |
09:50 ET | 1071 | 9.0843 |
09:52 ET | 1471 | 9 |
09:54 ET | 422 | 9.04 |
09:56 ET | 600 | 8.98 |
09:57 ET | 500 | 8.97 |
09:59 ET | 6262 | 9 |
10:01 ET | 200 | 9 |
10:03 ET | 316 | 8.95 |
10:06 ET | 7209 | 8.88 |
10:08 ET | 1040 | 8.86 |
10:10 ET | 1300 | 8.92 |
10:14 ET | 400 | 8.86 |
10:15 ET | 100 | 8.85 |
10:17 ET | 623 | 8.88 |
10:21 ET | 11330 | 8.77 |
10:24 ET | 1707 | 8.78 |
10:26 ET | 2800 | 8.77 |
10:28 ET | 1000 | 8.82 |
10:30 ET | 338 | 8.84 |
10:32 ET | 100 | 8.85 |
10:33 ET | 300 | 8.85 |
10:35 ET | 1525 | 8.8 |
10:37 ET | 500 | 8.81 |
10:39 ET | 1500 | 8.85 |
10:44 ET | 1200 | 8.82 |
10:46 ET | 500 | 8.79 |
10:48 ET | 1350 | 8.7505 |
10:50 ET | 238 | 8.74 |
10:51 ET | 865 | 8.71 |
10:53 ET | 938 | 8.75 |
10:55 ET | 8055 | 8.7934 |
10:57 ET | 30575 | 8.74 |
11:00 ET | 3805 | 8.68 |
11:02 ET | 1495 | 8.65 |
11:04 ET | 3540 | 8.68 |
11:08 ET | 414 | 8.63 |
11:09 ET | 833 | 8.605 |
11:11 ET | 6299 | 8.645 |
11:13 ET | 2714 | 8.7169 |
11:15 ET | 309 | 8.69 |
11:18 ET | 9883 | 8.645 |
11:20 ET | 7116 | 8.66 |
11:22 ET | 2200 | 8.6503 |
11:24 ET | 4316 | 8.7 |
11:26 ET | 700 | 8.6901 |
11:27 ET | 1161 | 8.71 |
11:29 ET | 1517 | 8.685 |
11:31 ET | 776 | 8.695 |
11:33 ET | 1683 | 8.69 |
11:36 ET | 820 | 8.68 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Replimune Group Inc | 627.9M | -2.7x | --- |
Olema Pharmaceuticals Inc | 623.1M | -5.2x | --- |
Phathom Pharmaceuticals Inc | 632.8M | -2.4x | --- |
Humacyte Inc | 639.5M | -5.2x | --- |
Savara Inc | 641.2M | -12.1x | --- |
Oculis Holding AG | 549.7M | -6.5x | --- |
Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $627.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 67.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-3.24 |
Book Value | $6.10 |
P/E Ratio | -2.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.